Haihong Zhong

Haihong Zhong


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 December 2024 in Journal of Hazardous Materials
Verified
Journal Article
Closed access
YWYuan Wang
Yuan Wang
HZHaihong Zhong
Haihong Zhong
QXQianqian Xu
Qianqian Xu
MDMiao Dong
Miao Dong
JYJianxin Yang
Jianxin Yang
ZSZhong-Min Su
Zhong-Min Su

28 February 2024 in Small Science
Verified
Journal Article
Open access
KXKexin Xu
Kexin Xu
HZHaihong Zhong
Haihong Zhong
XLXuying Li
Xuying Li
JSJie Song
Jie Song
LELuis Alberto Estudillo‐Wong
Luis Alberto Estudillo‐Wong
Nicolas Alonso-VanteNicolas Alonso-Vante
Nicolas Alonso-Vante
The design and development of highly efficient electrocatalysts for oxygen evolution reaction (OER) are critical for renewable energy generation. Ni‐based electrocatalysts are widely used in the water electrolysis process. In this work, heterostructure consisting of selenides and layered double hydroxides (LDH) named (Co, Ni)Se4@NiFe‐LDH, are prepared by an LDH‐based strategy, in which the electronic structure of Ni active sites is regulated by interfacial electron interaction. The (Co, Ni)Se4@NiFe‐LDH shows an optimized charge distribution of Ni sites and excellent catalytic activity. The effective charge modulation results in lowering the energy barrier of OOH* intermediate formation and adequate adsorption strength of the intermediates on Ni‐active sites, which improves the kinetics of OER. Specifically, the (Co, Ni)Se4@NiFe‐LDH only requires an overpotential of 237 mV to reach the current density of 10 mA cm−2 under alkaline conditions. The results of this work demonstrate that reasonable engineering of heterostructure is an effective strategy to improve the intrinsic property of OER electrocatalysts for water splitting.

8 September 2023 in Advanced Energy and Sustainability Research
Verified
Journal Article
Open access
YWYuan Wang
Yuan Wang
HZHaihong Zhong
Haihong Zhong
WYWeiting Yang
Weiting Yang
Yongjun FengYongjun Feng
Yongjun Feng
Nicolas Alonso-VanteNicolas Alonso-Vante
Nicolas Alonso-Vante
The oxygen reduction reaction (ORR) plays a pivotal role in electrochemical energy conversion and chemical production. Two‐electron (2e−) charge transfer for oxygen reduction is considered a promising method for the on‐site production of hydrogen peroxide (H2O2), which requires electrocatalysts with high H2O2 selectivity and ORR activity. Noble metal alloys (e.g., Pt‐Hg and Pd‐Hg) have been prevalent materials of choice due to their desirable intrinsic activity, but their scarcity and high cost seriously hinder their widespread application in practice. Self‐doped heteroatomic carbon‐based electrocatalysts, derived from abundant and inexpensive biomass, have emerged as attractive candidates for on‐site H2O2 production. This review summarizes the fundamentals and recent advances in H2O2 production via 2e− ORR, including basic catalytic mechanisms, the influence of electrolyte pH and porous structure of catalysts, selectivity assessment methods, determination of the cumulative H2O2 concentration, development of biomass‐derived carbon‐based catalyst, and electrochemical device designs. Current challenges and proposed opportunities are also presented with an emphasis on large‐scale electrochemical H2O2 synthesis.

18 November 2021 in Catalysts
Verified
Journal Article
Open access
PDF file
JWJing Wang
Jing Wang
HKHeng Kong
Heng Kong
HZHaihong Zhong
Haihong Zhong
YJYu Jiang
Yu Jiang
FGFei Guo
Fei Guo
Yongjun FengYongjun Feng
Yongjun Feng
The oxygen reduction reaction (ORR) and oxygen evolution reaction (OER), namely, so-called oxygen electrode reactions, are two fundamental half-cell reactions in the energy storage and conversion devices, e.g., zinc–air batteries and fuel cells. However, the oxygen electrode reactions suffer from sluggish kinetics, large overpotential and complicated reaction paths, and thus require efficient and stable electrocatalysts. Transition-metal-based layered double hydroxides (LDHs) and their derivatives have displayed excellent catalytic performance, suggesting a major contribution to accelerate electrochemical reactions. The rational regulation of electronic structure, defects, and coordination environment of active sites via various functionalized strategies, including tuning the chemical composition, structural architecture, and topotactic transformation process of LDHs precursors, has a great influence on the resulting electrocatalytic behavior. In addition, an in-depth understanding of the structural performance and chemical-composition-performance relationships of LDHs-based electrocatalysts can promote further rational design and optimization of high-performance electrocatalysts. Finally, prospects for the design of efficient and stable LDHs-based materials, for mass-production and large-scale application in practice, are discussed.

14 December 2016 in mAbs
Verified
Journal Article
Open access
BBBinyam Bezabeh
Binyam Bezabeh
RFRyan Fleming
Ryan Fleming
CFChristine Fazenbaker
Christine Fazenbaker
HZHaihong Zhong
Haihong Zhong
KCKaren Coffman
Karen Coffman
NDNazzareno Dimasi
Nazzareno Dimasi
By simultaneous binding two disease mediators, bispecific antibodies offer the opportunity to broaden the utility of antibody-based therapies. Herein, we describe the design and characterization of Bs4Ab, an innovative and generic bispecific tetravalent antibody platform. The Bs4Ab format comprises a full-length IgG1 monoclonal antibody with a scFv inserted into the hinge domain. The Bs4Ab design demonstrates robust manufacturability as evidenced by MEDI3902, which is currently in clinical development. To further demonstrate the applicability of the Bs4Ab technology, we describe the molecular engineering, biochemical, biophysical, and in vivo characterization of a bispecific tetravalent Bs4Ab that, by simultaneously binding vascular endothelial growth factor and angiopoietin-2, inhibits their function. We also demonstrate that the Bs4Ab platform allows Fc-engineering similar to that achieved with IgG1 antibodies, such as mutations to extend half-life or modulate effector functions.

1 May 2018 in Oncotarget
Verified
Journal Article
Open access
PDF file
EBEmily E. Bosco
Emily E. Bosco
RCR. James Christie
R. James Christie
RCRosa Carrasco
Rosa Carrasco
DSDarrin Sabol
Darrin Sabol
JZJiping Zha
Jiping Zha
DTDavid A. Tice
David A. Tice
// <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> Emily E. Bosco1, R. James Christie2, Rosa Carrasco1, Darrin Sabol1, Jiping Zha3, 8, Karma DaCosta3, Lee Brown4, Maureen Kennedy1, John Meekin1, Sandrina Phipps2, Joanne Ayriss2, 6, Qun Du2, Binyam Bezabeh2, 7, Partha Chowdhury2, 9, Shannon Breen1, Cui Chen1, Molly Reed5, MaryJane Hinrichs5, Haihong Zhong1, Zhan Xiao1, Rakesh Dixit5, Ronald Herbst1 and David A. Tice1 1Oncology Research, MedImmune, LLC, Gaithersburg, Maryland, United States of America 2Antibody Discovery and Protein Engineering, MedImmune, LLC, Gaithersburg, Maryland, United States of America 3Pathology, MedImmune, LLC, Gaithersburg, Maryland, United States of America 4Pathology, MedImmune, Ltd, Cambridge, United Kingdom 5Biologics Safety Assessment, MedImmune, LLC, Gaithersburg, Maryland, United States of America 6Department of Global Biotherapeutics, Pfizer, Cambridge, Massachusetts, United States of America 7Research, Salubris Biotherapeutics, Gaithersburg, Maryland, United States of America 8Translational Sciences, NGM Biopharmaceuticals, South San Francisco, California, United States of America 9Biologics Discovery, Sanofi Genzyme, Cambridge, MA, United States of America *These authors contributed equally to this work Correspondence to: Emily E. Bosco, email: boscoe@medimmune.com Keywords: GFRA1; antibody-drug conjugate (ADC); pyrrolobenzodiazepine (PBD); anti-tumor activity; breast cancer Received: January 12, 2018 Accepted: April 05, 2018 Published: May 01, 2018 ABSTRACT Despite recent advances in treatment, breast cancer remains the second-most common cause of cancer death among American women. A greater understanding of the molecular characteristics of breast tumors could ultimately lead to improved tumor-targeted treatment options, particularly for subsets of breast cancer patients with unmet needs. Using an unbiased genomics approach to uncover membrane-localized tumor-associated antigens (TAAs), we have identified glial cell line derived neurotrophic factor (GDNF) family receptor α 1 (GFRA1) as a breast cancer TAA. Immunohistochemistry (IHC) revealed that GFRA1 displays a limited normal tissue expression profile coupled with overexpression in specific breast cancer subsets. The cell surface localization as determined by fluorescence-activated cell sorting (FACS) and the rapid internalization kinetics of GFRA1 makes it an ideal target for therapeutic exploitation as an antibody-drug conjugate (ADC). Here, we describe the development of a pyrrolobenzodiazepine (PBD)-armed, GFRA1-targeted ADC that demonstrates cytotoxicity in GFRA1-positive cell lines and patient-derived xenograft (PDX) models. The safety profile of the rat cross-reactive GFRA1-PBD was assessed in a rat toxicology study to find transient cellularity reductions in the bone marrow and peripheral blood, consistent with known off-target effects of PBD ADC’s. These studies reveal no evidence of on-target toxicity and support further evaluation of GFRA1-PBD in GFRA1-positive tumors.